Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer

[1]  S. Bowen,et al.  Treatment Intensification in Locally Advanced/Unresectable NSCLC Through Combined Modality Treatment and Precision Dose Escalation. , 2021, Seminars in radiation oncology.

[2]  Sabyasachi Chakraborty,et al.  Critical benchmarking of popular composite thermochemistry models and density functional approximations on a probabilistically pruned benchmark dataset of formation enthalpies. , 2021, The Journal of chemical physics.

[3]  Jingyun Shi,et al.  Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens. , 2021, The British journal of radiology.

[4]  K. Kaira,et al.  Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers , 2021, Cancer Imaging.

[5]  Sayoni Das,et al.  CATH functional families predict functional sites in proteins , 2020, Bioinform..

[6]  C. Aspord,et al.  T‐cell receptor diversity as a prognostic biomarker in melanoma patients , 2020, Pigment cell & melanoma research.

[7]  Nitin Ohri,et al.  18F-Fluorodeoxyglucose PET in Locally Advanced Non-small Cell Lung Cancer: From Predicting Outcomes to Guiding Therapy. , 2020, PET clinics.

[8]  D. Planchard,et al.  Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Sohini Ramachandran,et al.  Germline features associated with immune infiltration in solid tumors , 2019, bioRxiv.

[10]  Helen H. W. Chen,et al.  Prognostic value of volumetric metabolic parameter changes determined by during and after radiotherapy‐based 18F‐FDG PET/CT in stage III non‐small cell lung cancer , 2019, The Kaohsiung journal of medical sciences.

[11]  K. Frey,et al.  Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  J. Sonke,et al.  The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[14]  A. Bezjak,et al.  Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non–small‐cell Lung Cancer (NCT02788461) , 2018, Clinical lung cancer.

[15]  R. Ferris,et al.  T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response , 2018, Oncoimmunology.

[16]  Yufeng Shen,et al.  Quantifying size and diversity of the human T cell alloresponse. , 2018, JCI insight.

[17]  R. Weichselbaum,et al.  Type 3 innate lymphoid cell-derived lymphotoxin prevents microbiota-dependent inflammation , 2017, Cellular & Molecular Immunology.

[18]  Arnaud Boyer,et al.  Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.

[19]  Julian C. Hong,et al.  Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Randall K Ten Haken,et al.  Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer: A Phase 2 Clinical Trial , 2017, JAMA oncology.

[21]  Paul E Kinahan,et al.  Functional lung avoidance and response‐adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy , 2017, Medical physics.

[22]  P. Hainaut,et al.  Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications , 2017, BioMed research international.

[23]  Reshma Jagsi,et al.  Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. , 2017, International journal of radiation oncology, biology, physics.

[24]  Ralph R. Weichselbaum,et al.  Radiotherapy and immunotherapy: a beneficial liaison? , 2017, Nature Reviews Clinical Oncology.

[25]  R. Weichselbaum,et al.  Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma , 2016, Oncotarget.

[26]  P. Rosenstiel,et al.  Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. , 2016, Immunity.

[27]  R. Govindan,et al.  PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Martin A Lodge,et al.  Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. , 2016, Radiology.

[29]  Jedd D. Wolchok,et al.  Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma , 2015, Journal of Immunotherapy for Cancer.

[30]  U. Bora,et al.  Data in support of in vivo studies of silk based gold nano-composite conduits for functional peripheral nerve regeneration , 2015, Data in brief.

[31]  Fabrice Denis,et al.  Early Assessment of Metabolic Response by 18F-FDG PET During Concomitant Radiochemotherapy of Non–Small Cell Lung Carcinoma Is Associated With Survival: A Retrospective Single-Center Study , 2015, Clinical nuclear medicine.

[32]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[33]  E. Golden,et al.  Radiotherapy and immunogenic cell death. , 2015, Seminars in radiation oncology.

[34]  R. Perez-soler,et al.  Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer. , 2015, Lung cancer.

[35]  A. Chao,et al.  An improved nonparametric lower bound of species richness via a modified good–turing frequency formula , 2014, Biometrics.

[36]  You Lu,et al.  Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local Control in Non–Small-Cell Lung Cancer Receiving Radiotherapy , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  Timothy Daley,et al.  Predicting the molecular complexity of sequencing libraries , 2013, Nature Methods.

[38]  Philippe Lambin,et al.  Response Assessment Using 18F-FDG PET Early in the Course of Radiotherapy Correlates with Survival in Advanced-Stage Non–Small Cell Lung Cancer , 2012, The Journal of Nuclear Medicine.

[39]  Kristin D. Brockway,et al.  What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. , 2012, International journal of radiation oncology, biology, physics.

[40]  Benjamin Movsas,et al.  Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. , 2012, International journal of radiation oncology, biology, physics.

[41]  Baosheng Li,et al.  Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[43]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[44]  Michalis Aristophanous,et al.  The development and testing of a digital PET phantom for the evaluation of tumor volume segmentation techniques. , 2008, Medical physics.

[45]  P. McCullagh.  Estimating the Number of Unseen Species: How Many Words did Shakespeare Know? , 2008 .

[46]  D. Ettinger,et al.  Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  W. Bossert,et al.  The Measurement of Diversity , 2001 .

[48]  B. Efron,et al.  Estimating the number of unseen species: How many words did Shakespeare know? Biometrika 63 , 1976 .

[49]  E. C. Pielou.  The measurement of diversity in different types of biological collections , 1966 .